<DOC>
	<DOCNO>NCT01163435</DOCNO>
	<brief_summary>Up , knowledge , randomize , large scale study prospectively simultaneously compare efficacy , adverse effect patient adherence current recommend 1st-line 2nd-line regimen H. pylori eradication country . The aim study : 1. compare efficacy high dose dual therapy , sequential therapy clarithromycin-based triple therapy 1st-line regimen H. pylori eradication ; 2. compare efficacy high dose dual therapy , sequential therapy levofloxacin-based triple therapy rescue regimen H. pylori eradication ; 3. compare patient adherence adverse effect treatment regimens ; 4. investigate factor may influence H. pylorus eradication treatment regimens ; 5. investigate analyze prevalence trend antibiotic resistance .</brief_summary>
	<brief_title>Efficacy High Dose Dual Therapy , Sequential Therapy Triple Therapy H. Pylori Eradication</brief_title>
	<detailed_description>Patients H. pylori-positive chronic gastritis with/without peptic ulcer recruit . All undergo endoscopy biopsy treatment . Four eight week termination treatment , H. pylori infection status examine endoscopy biopsy Carbon 13-urea breath test patient refuse second endoscopy . The cytochrome P450 ( CYP ) 2C19 genotype participant analyze polymerase chain reaction-based restriction fragment length polymorphism ( PCR-RFLP ) method . A compute generated random number sequence block three subgroup , say A1 , B1 C1 ( A2 , B2 , C2 ) . If patient receive anti-H. pylorus therapy previously , invite enter first part study evaluate efficacy 1st-line regimen . If patient receive anti-H. pylori therapy previously , invited enter second part study evaluate efficacy rescue regimen . Patients meet inclusion criterion one exclusion criterion randomize receive one follow regimen : - 1st-line regimen : group A1 - high dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid 14 day ) ; group B1 - sequential therapy ( rabeprazole 20 mg + amoxicillin 1000 mg , bid 5 day , rabeprazole 20 mg + metronidazole 500 mg + clarithromycin 500 mg , bid next 5 day ) ; group C1 - clarithromycin-based triple therapy ( rabeprazole 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg , bid 7 day ) . - rescue regimen : group A2 - high dose dual therapy ( group A1 ) ; group B2 - sequential therapy ( group B1 ) ; group C2 - levofloxacin-based triple therapy ( rabeprazole 20 mg + amoxicillin 1000 mg + levofloxacin 250 mg , bid 7 day ) . All patient ask complete questionnaire record symptoms drug consumption daily treatment period . Post-treatment , patient see Outpatients Clinic investigate patient adherence adverse effect treatment .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>patient H. pylori relate chronic gastritis with/without peptic ulcer age great 18 year willing receive eradication therapy . pregnant nursing woman serious concomitant illness malignant tumor kind history hypersensitivity test drug serious bleed course ulcer previous gastric surgery receive bismuth salt , proton pump inhibitor , antibiotic previous month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>antibiotic resistance</keyword>
	<keyword>high dose dual therapy</keyword>
	<keyword>sequential therapy</keyword>
	<keyword>clarithromycin-based triple therapy</keyword>
	<keyword>levofloxacin-based triple therapy</keyword>
</DOC>